Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA

Kairos Pharma, LTD.

Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.
Underwriters granted 45-day option for additional 232,500 shares at same price.
Proceeds to fund Phase 1 lung cancer and Phase 2 prostate cancer trials for lead candidate ENV 105.
Issued two warrants to underwriters for 54,250 shares each at $4.80 exercise price, exercisable from Mar 2025 to Sep 2029.
Common stock began trading on NYSE American on Sept 16, 2024 under symbol KAPA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.